Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Comparative Study of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
MiMedx Group, Inc.
ClinicalTrials.gov Identifier:
NCT01552499
First received: March 6, 2012
Last updated: September 14, 2012
Last verified: September 2012
  Purpose

The purpose of this study is to determine whether the EpiFix human amniotic membrane is effective in the treatment of diabetic foot ulcers.


Condition Intervention
Diabetic Foot Ulcer
Other: Standard of care
Other: Applications of EpiFix

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: A Prospective, Randomized, Comparative Parallel Study of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers

Resource links provided by NLM:


Further study details as provided by MiMedx Group, Inc.:

Primary Outcome Measures:
  • The proportion of completely healed ulcers in patients treated with amniotic membrane vs. standard of care [ Time Frame: 12 week ]

Secondary Outcome Measures:
  • Percent change in wound area [ Time Frame: 4 week ]
  • Mean time to complete healing [ Time Frame: Up to 12 weeks ]

Enrollment: 25
Study Start Date: March 2012
Study Completion Date: August 2012
Arms Assigned Interventions
Control Other: Standard of care
Experimental: Treatment Other: Standard of care Other: Applications of EpiFix

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Male or female age 18 or older
  • Informed consent must be obtained
  • Patient's ulcer must be diabetic in origin and larger than 1cm2. Debridement will be done prior to randomization. Subject's informed consent for participating in this study, must be obtained prior to proceeding with sharp debridement.
  • Patients with Type 1 or Type 2 diabetes (criteria for the diagnosis of diabetes mellitus per ADA).
  • Ulcer must be present for a minimum of four weeks direction, with documented failure of prior treatment to heal the wound.
  • Patient's ulcer must exhibit no clinical signs of infection.
  • Patient is of legal consenting age.
  • Patient is willing to provide informed consent and is willing to participate in all procedures and follow up evaluations necessary to complete the study.
  • Serum Creatine less then 3.0mg/dl
  • HbA1c less than 12%
  • Patient has adequate circulation to the affected extremity, as demonstrated by one of the following within the past 60 days:

    • Dorsum transcutaneous oxygen test (TcPO2) with results ≥30mmHg, OR
    • ABIs with results of ≥0.7 and ≤1.2, OR
    • Doppler arterial waveforms, which are triphasic or biphasic at the ankle of affected leg

Exclusion Criteria:

  • Patients presenting with an ulcer probing to bone (UT Grade IIIA-D). A positive probe-to-bone will be confirmed when bone or joint can be felt with a sterile, ophthalmological probe.
  • Patients whose index diabetic foot ulcers are greater than 25cm2.
  • Patients considered not in reasonable metabolic control, confirmed by an HbA1c greater than 12% within previous 90 days,
  • Patients whose serum creatinine levels are 3.0mg/dl or greater.
  • Patients with a known history of poor compliance with medical treatments.
  • Patients who have been previously randomized into this study, or are presently participating in another clinical trial.
  • Patients who are currently receiving radiation therapy or chemotherapy.
  • Patients with known or suspected local skin malignancy to the index diabetic ulcer.
  • Patients on anticoagulant medication will as in any surgical procedure, be monitored according to the protocols employed at the enrolling center.
  • Patients diagnosed with autoimmune connective tissues diseases.
  • Non-revascularizable surgical sites.
  • Active infection at site.
  • Any pathology that would limit the blood supply and compromise healing.
  • Patients that have received a biomedical or topical growth factor for their wound within the previous 30 days.
  • Patient who are pregnant or breast feeding.
  • Patient who are taking medications that are considered immune system modulator which could affect graft incorporation.
  • Allergy to Gentamycin or Streptomycin.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01552499

Locations
United States, Virginia
Professional Education and Research Institute
Roanoke, Virginia, United States, 24016
Sponsors and Collaborators
MiMedx Group, Inc.
Investigators
Principal Investigator: Charles M. Zelen, DPM Professional Education and Research Institute
  More Information

No publications provided

Responsible Party: MiMedx Group, Inc.
ClinicalTrials.gov Identifier: NCT01552499     History of Changes
Other Study ID Numbers: EPIFIX002
Study First Received: March 6, 2012
Last Updated: September 14, 2012
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Diabetic Foot
Foot Ulcer
Ulcer
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Diabetic Angiopathies
Diabetic Neuropathies
Endocrine System Diseases
Foot Diseases
Leg Ulcer
Pathologic Processes
Skin Diseases
Skin Ulcer
Vascular Diseases

ClinicalTrials.gov processed this record on November 25, 2014